-+ 0.00%
-+ 0.00%
-+ 0.00%

NovaBridge Biosciences Doses First Participant In Phase 2 Combination Trial Of Givastomig With Nivolumab And Chemotherapy In Patients With HER2-Negative, 1L Metastatic Gastric Cancer

Benzinga·02/17/2026 21:22:20
Listen to the news

NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced enrollment of the first patient in the global Phase 2 randomized combination study evaluating givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy (mFOLFOX6) in patients with HER2-negative, 1L metastatic gastric cancer. Positive Phase 1b data position givastomig to be a potential best-in-class CLDN18.2-directed therapy for gastric cancer with a projected $12 billion market opportunity by 20301. Top line Phase 2 results are expected in 2027.